

Partnership for Vivax Elimination

PAVE

Training workshop

[Country, date]

Training goals for participants

- To ensure **comprehensive understanding of the importance of testing for G6PD and treating vivax malaria for patients and their communities**
- To demonstrate full competency in **[the use, and]** interpretation of quantitative G6PD test results and treatment algorithms
- **[To provide appropriate vivax treatment based on the results of the G6PD tests]**

Training agenda

Partnership for Vivax Elimination

PAVE

We want you to talk to us throughout the training session. Which means:

- We want to hear about your experiences and thoughts on malaria
- Share your thoughts on the new tools that we are introducing to you
- Participate in role-plays
- Think through scenarios that you will face in your health facilities
- We will do pre and post– session quizzes for two reasons:
 - to see what you understand and what needs additional explanation, and
 - understand how we can improve the training and determine whether you can perform testing and treatment of vivax malaria

by the end of this training workshop you should be able to:

- Describe *P. vivax* malaria and its importance in **your country**
- Understand **G6PD testing and why it is needed in the treatment of vivax malaria**
- Explain how G6PD deficiency affects the choice of treatment for *P. vivax* malaria
- **Set up of the G6PD analyzer**
- **Prepare all components needed for G6PD testing**
- **Explain the test procedure for measuring patients G6PD activity**
- **Interpret** the results of the G6PD test
- **Perform the SD Biosensor quantitative G6PD test**
- Understand common user mistakes when performing the test

by the end of this training workshop you should be able to:

- **Understand how to use primaquine and tafenoquine in the management of liver-stage uncomplicated *P. vivax* malaria**
- **Identify ways to reduce risk of severe adverse events and in particular, hemolysis**
- **Provide patients with information about side effects that they need to report to health workers**
- **Understand the potential side effects of primaquine [and tafenoquine] that should be explained to patients**
- **Describe how to report adverse events from your facility to higher levels**
- **Describe how new diagnostic tests and primaquine [or tafenoquine] will be incorporated into your health facility**
- **Explain how data will be recorded and reported at and from your health facility**

Quantitative G6PD test by SD Biosensor



- The STANDARD G6PD test is a point-of-care test that can be used in health facilities
- This test measures the amount of G6PD activity in patients' blood
- Results are available in two minutes
- Samples can be either come from fingerprick or venous blood



**Tafenoquine
(TQ)**

- Tafenoquine is a single-dose treatment for liver-stage infection of *P. vivax* malaria
- TQ is an 8-aminoquinoline like primaquine
- The TQ dose consists of 2 x 150 mg tablets taken at one time
- TQ can only be taken by patients who have normal G6PD activity (*where normal G6PD activity is defined as > 70%*)
- TQ can only be taken by patients who are 16 years and over

- You will complete a quiz before and after training so that we can assess if the learning objectives are **met**
- **The quiz will also assess whether you can competently test [and treat] vivax patients**
- We will also ask you questions throughout the training to make sure we are training you properly
- [We will assess you on your ability to use a quantitative G6PD test]

- **You will have 45 minutes to complete the quiz**
- **Please write your name, participant number and health facility at the top of your quiz sheet**
- **Please circle answers**
- **Note, some questions can have multiple choice questions**